Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
暂无分享,去创建一个
Patrick Durez | M. Genovese | V. Mazurov | P. Durez | Sang-Heon Lee | H. Kellner | C. Codding | J. Supronik | Shephard Mpofu | Mark C Genovese | Sang-Heon Lee | Herbert Kellner | Hanno B Richards | Jerzy Supronik | Eva Dokoupilova | Vadim Mazurov | Jacob A Aelion | Christine E Codding | Takashi Ikawa | Sophie Hugot | H. Richards | E. Dokoupilová | S. Hugot | J. Aelion | S. Mpofu | T. Ikawa
[1] S. Nakae,et al. Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1 , 2003, The Journal of Immunology.
[2] J. Banchereau,et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.
[3] P. Miossec,et al. IL-17 as a future therapeutic target for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.
[4] L. Joosten,et al. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis , 2001, Arthritis research.
[5] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[6] W. Gross,et al. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. , 2008, Clinical and experimental rheumatology.
[7] K. Hillan,et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. , 2001, Cytokine.
[8] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[9] D. Furst. The risk of infections with biologic therapies for rheumatoid arthritis. , 2010, Seminars in arthritis and rheumatism.
[10] R. Chang,et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. , 1992, Arthritis and rheumatism.
[11] T. Martin,et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.
[12] V. Kuchroo,et al. Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.
[13] T. Pincus,et al. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. , 2002, The Journal of rheumatology.
[14] A. Skapenko,et al. Role of Th17 cells in human autoimmune arthritis. , 2010, Arthritis and rheumatism.
[15] Kaleb Michaud,et al. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases , 2009, Arthritis research & therapy.
[16] T. Moseley,et al. Interleukin-17 family and IL-17 receptors. , 2003, Cytokine & growth factor reviews.
[17] L. Joosten,et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. , 2004, Arthritis and rheumatism.
[18] P. Tak,et al. Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.
[19] J. Barton,et al. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy , 2009, Patient preference and adherence.
[20] T. Pincus,et al. Mortality in rheumatoid arthritis: 2008 update. , 2008, Clinical and experimental rheumatology.
[21] B. Kirkham,et al. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. , 2002, Arthritis and rheumatism.
[22] Yulan He,et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. , 1998, Journal of immunology.
[23] P. Miossec. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. , 2003, Arthritis and rheumatism.
[24] D. Furst,et al. Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis , 2010, The Korean journal of internal medicine.
[25] K. Książek,et al. Interleukin-17: a mediator of inflammatory responses , 2004, Cellular and Molecular Life Sciences CMLS.